Cutaneous and ocular side-effects of oral photochemotherapy: results of an 8-year follow-up study.
To determine the long-term cutaneous side-effects of oral photochemotherapy (PUVA), we examined 95 patients, 59 with psoriasis and 36 with mycosis fungoides (MF). These comprised 80% and 69% respectively of the patients with these disorders treated with PUVA in our department from 1977 to 1985. Two psoriatic patients had squamous carcinomas, both of whom had received high cumulative UVA doses and also methotrexate concurrently with PUVA. Six patients with MF had actinic keratoses. The mean age of these patients (69 years) was significantly greater than the mean age of the patients without actinic keratoses (54 years), but there was no significant difference in their cumulative UVA doses. No patients developed basal cell carcinomas or malignant melanoma. 'PUVA lentigines' were found in 46% of the patients. They were most frequent in patients currently being treated and in those who had received high cumulative UVA doses, but persisted for up to 7 years after discontinuing therapy. Seventy-one patients had yearly ophthalmological examinations, or a single examination at least 3 months after commencing PUVA. This examination included retinal function tests to detect any subclinical visual impairment. Five of these patients had cataract prior to PUVA therapy, and were significantly older (mean age 71 years) than those without cataract (mean age 53 years). Three patients (mean age 61 years) developed new lens opacities whilst receiving PUVA. However, none of these patients was considered to have cataract as none had impairment of visual acuity due to lens opacity. No patients without lens opacity developed evidence of subclinical visual impairment.
D000199:Actins; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced; D005123:Eye / Q000187:drug effects; D005128:Eye Diseases / Q000139:chemically induced*; D005500:Follow-Up Studies; D006801:Humans; D007642:Keratosis / Q000139:chemically induced; D007911:Lentigo / Q000139:chemically induced; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy; D011701:PUVA Therapy / Q000009:adverse effects*; D011565:Psoriasis / Q000188:drug therapy; D012871:Skin Diseases / Q000139:chemically induced*; D012878:Skin Neoplasms / Q000139:chemically induced; D014792:Visual Acuity / Q000187:drug effects
D000199:Actins